AMEX
62.38USD
+0.18 (+0.29%)
We have scored 5 news catalysts on ALPS Medical Breakthroughs ETF (SBIO) over the past 12 months. The biggest single-day move next to one of them came May 25, 2026, when SBIO closed −0.9%: “Sabio Announces First Quarter 2026 Results”. Coverage across the window leans positive (average ticker sentiment +0.70). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
198.1M
P/E
—
EPS
—
Beta
0.95
52W range
36.84-70.85
Day range
62.14–63.02
Open
62.80
Prev close
62.20
Volume
35.8K
Avg volume
37.6K
Dividend
0.00
IPO
2014-12-30
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about ALPS Medical Breakthroughs ETF — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for SBIO: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
